1412P Immune changes after enzalutamide (Enza) is added to androgen-deprivation therapy (ADT) in first-line metastatic castration-resistant prostate cancer (mCRPC)Ravi A. Madan, James L. Gulley, Renee N. Donahue et al.|Annals of Oncology|2022Cited by 2
Safety profile of therapeutic pox virus-based vaccines for cancerH Kaufman, Thomas Schuetz, H. Kim Lyerly et al.|Journal of Clinical Oncology|2004Cited by 0